Clinical trial
Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic…
NCT00038597 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00038597 |
|---|---|
| Title | Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML) |
| Official title | Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML) |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myelogenous Leukemia, Chronic |
| Intervention type | Drug |
| Interventions | SCH66336 |
| Enrollment | 13 |
| Start date | Apr 30, 2001 |
| Primary completion | May 7, 2004 |
| Completion | May 7, 2004 |
| First posted | Jun 4, 2002 |
| Last update posted | Oct 30, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: